Recent works have demonstrated that HDAC inhibitors can attenuate the inflammatory profile in DSS-induced colitis models by suppressing local secretion of pro-inflammatory cytokines and chemokines and also by suppressing mobilization and accumulation of inflammatory cells [26]. Here, HDAC9 is linked to colitis.